STABILITY-INDICATING HPLC METHOD FOR THE DETERMINATION OF RELATED SUBSTANCES IN LANSOPRAZOLE INTERMEDIATE
Keywords:Lansoprazole Intermediate, HPLC, Validation, Impurities, Stress Study
A novel, reversed-phase liquid chromatographic method was developed and validated for the determination of related substances in lansoprazole intermediate. Symmetric peak shape was on a C18 stationary phase with the dimensions of 250 mm column length, 4.6 mm as internal diameter, 5 microns particles with an economical and straightforward mass-compatible mobile phase combination of formic acid/triethylamine and acetonitrile delivered in gradient mode at a flow rate of 1.0 mL/min at 260 nm. The resolution between lansoprazole intermediate (LAN20) and its impurities (LAN20-I & LAN20-II) in the developed method was more than 2.0, indicating a significant separation. Regression analysis shows a correlation coefficient greater than 0.999 for lansoprazole intermediate and its related substances. The detection and quantitation limits of lansoprazole intermediate and its impurities are 0.01% and 0.005%. This method indicates that the recovery at different levels is 90 to 110% accurate. The test solution was stable in the diluent for 48 h and subjected to stress conditions. The mass balance was close to 99.5%.
Blvd, S.V. and Diego, S.G.S (2014). ICH Harmonised tripartite guideline-Validation of analytical procedures: text and methodologyQ2(R1). https://somatek.com/wp-content/uploads/2014/06/sk140605h.pdf
Chorghade, M. S. (2006). Drug Discovery and Development, Volume 1: Drug Discovery. 201. https://doi.org/10.1002/0471780103
Gangula, S. Elati, R.C. Neredla, A. Baddam, S.R. Neelam, U. Bandichhor, R. Dongamanti, A. (2010). An improved process for the production of lansoprazole: investigation of key parameters that influence the water content in final API. Org. Process Res. Dev, 14(1), 229- 233. https://doi.org/10.1021/op900258b
Hirschowitz, B.I. Mohnen, J. Shaw, S. (August 1996). Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment. Pharmacol. Ther. 10 (4). https://doi.org/10.1046/j.1365-2036.1996.10152000.x
ICH Harmonised (1996). guideline-Stability testing: Photostability testing of new drug substances and products Q1B. https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf
Lansoprazole Summary (2020). Lansoprazole - Drug Usage Statistics. ClinCalc. https://clincalc.com/DrugStats/Drugs/Lansoprazole
Pharmaceuticals, M. (2016). Lansoprazole capsule, delayed release pellets. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8fa7401-907f-41b6-a2e1-f4bc214f2cdf#:~:text=Lansoprazole%20delayed%2Drelease%20capsules%20are%20indicated%20in%20adults%20for%20reducing,Clinical%20Studies%20(14.6)%5D.
WIPO (2022). PATENTSCOPE, Wockhardt limited, Maharashtra, India. https://www.wipo.int/patentscope/en/
How to Cite
Copyright (c) 2022 Dr. Balaji Nagarajan, Dr. Gunasekar Manoharan
This work is licensed under a Creative Commons Attribution 4.0 International License.